Biotech in Belgium: news and updates

News and Trends 17 Dec 2019

Update: Cell Therapy Biotech Raises €47M to Fund NASH Clinical Trial

Update (17/12/2019): Promethera has increased the total raised in its Series D round to €47.2M with the addition of new investors, including Innovation Growth Ventures and Pegasus Tech Ventures among others. The round will fund two ongoing clinical trials and the start of at least two new trials outside Europe. Published on 07/05/2019 The Belgian […]

December 17, 2019 - 2 minutesmins - By Jonathan Smith

imcyse type 1 diabetes insulin immunotherapy

News and Trends 28 Aug 2019

Type 1 Diabetes Immunotherapy Shows Promise in Phase I

An immunotherapy designed by the Belgian biotech Imcyse to prevent type 1 diabetes has shown signs of clinical benefits and no major safety issues in a phase I trial. The phase I trial recruited 41 patients newly diagnosed with type 1 diabetes. Imcyse injected the patients with different doses of its treatment and monitored the […]

August 28, 2019 - 3 minutesmins - By Jonathan Smith

agrosavfe belgium strawberry pesticide fungal

News and Trends 30 Jul 2019

Belgian Biotech Raises €35M to Develop Eco-Friendly Pesticides

The Belgium-based company AgroSavfe has raised a Series C round of €35M to develop an environmentally friendly crop pesticide inspired by llama antibodies. AgroSavfe will use the funds to develop and manufacture its lead protein fungicide on a commercial scale. The company aims to get approval from the US Environmental Protection Agency and launch the […]

July 30, 2019 - 2 minutesmins - By Jonathan Smith

anthrax treatment belgium VIB nanobodies

More News! 17 Jul 2019

Scientists in Belgium Cure Anthrax in Mice by Smashing Bacteria’s Armor

Belgian researchers have developed a potential treatment for anthrax that breaks down the bacteria’s thick protein armor. Anthrax is a deadly type of bacteria famous for its use in terrorist attacks in 2001. Although anthrax infections can be treated with antibiotics, they can prove hard to treat when the bacteria are inhaled or ingested. Scientists […]

July 17, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 18 Jun 2019

Belgian Biotech’s €35M Series B to Fund Potential Type 1 Diabetes Cure

The Belgian company Imcyse has raised €35M in a Series B round to develop a potential cure for chronic autoimmune conditions including type 1 diabetes and multiple sclerosis. Imcyse will use the money to fund phase II trials of a peptide-based treatment for type 1 diabetes. The funds will also help the company to launch […]

June 18, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 7 May 2019

Belgian Biotech Raises €30M Series A to Unlock Undruggable Targets

Confo Therapeutics has raised €30M in a Series A round that will take its unique technology to find drugs for historically undruggable targets to clinical trials. The fundraising was led by the VCs BioGeneration Ventures and Wellington Partners, and joined by several other private and public investors. With the money, Confo Therapeutics aims to […]

May 7, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

crispr cas9 cassava crop virus resistance

News and Trends 29 Apr 2019

Viruses Evolve to Defeat CRISPR-Cas9 in Genetically-Modified Plants

Researchers found that viral pathogens can quickly evolve to overcome transgenic cassava plants expressing the bacterial weapon CRISPR-Cas9, which could have major regulatory implications. Geminiviruses are pathogens that kill off crops such as beans, cotton and cassava plants. Past efforts to breed plants that are resistant to infection have not been successful. One potential method […]

April 29, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 8 Apr 2019

AACR 2019: European Biotech Progresses in Fighting Cancer

The American Association for Cancer Research (AACR) met up in Atlanta, USA, to showcase the newest advances in cancer treatment from around the world. Sit back as we give you a quick rundown of the most interesting presentations from European organizations working to improve the treatment of cancer. Clinical trials In the conference last […]

April 8, 2019 - 4 minutesmins - By Jonathan Smith

llama leo pharma argen x skin milestone inflammatory

More News! 3 Apr 2019

€21M Series A to Finance Belgian Biotech’s Regenerative Antibodies

The Belgian biotech AgomAb has raised €21M and partnered with the Dutch biotech argenx to develop antibody treatments that could regenerate damaged tissue. The round was led by the Belgian investor V-Bio Ventures and Advent France Biotechnology. AgomAb will use the big Series A funding to test antibody treatments for fibrosis in clinical trials, as […]

April 3, 2019 - 2 minutesmins - By Jonathan Smith

Galapagos Gilead filgotinib rheumatoid arthritis

News and Trends 29 Mar 2019

Galapagos Nears First Drug Approval with Phase III Success in Rheumatoid Arthritis

Galapagos has released positive data from two phase III trials testing its flagship drug candidate, filgotinib, that will let the company and its partner Gilead apply for marketing approval. 20 years after its foundation, Galapagos is finally approaching the finish line. Yesterday, the company has shared positive data from two clinical trials that together enrolled […]

March 29, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

arthritis pediatric juvenile idiopathic Leuven

News and Trends 13 Mar 2019

Artificial Intelligence Detects Juvenile Arthritis in the Blood

Using artificial intelligence, a Belgian research group can diagnose juvenile arthritis from blood samples with almost 90% accuracy and identify different forms of the disease, something that is not currently possible. Juvenile idiopathic arthritis causes joint pain, swelling and stiffness in children under the age of 16. The disease is hard to treat because there […]

March 13, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 14 Nov 2018

CAR-T Promise for Patients with Solid Tumors

A new CAR-T cancer therapy from the Belgian company Celyad has shown early positive results against solid tumors in two Phase I trials, including one trial that did not include add-on chemotherapy. In one ongoing Phase I trial, Celyad’s CAR-T therapy, combined with chemotherapy, successfully shrank tumors in three enrolled patients with aggressive colorectal cancer. One […]

November 14, 2018 - 3 minutesmins - By Jonathan Smith

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us